EPA:SAN - Sanofi Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
€66.17 -0.06 (-0.09 %)
(As of 07/19/2018 04:00 PM ET)
Previous Close€66.23
Today's Range€65.87 - €66.58
52-Week Range€63.09 - €92.97
Volume6.89 million shs
Average Volume3.05 million shs
Market Capitalization$82.98 billion
P/E RatioN/A
Dividend Yield4.58%
BetaN/A
Sanofi logoSanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulator and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for various cancers; Eloxatin, a platinum agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer for hematologic malignancies; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; and Praluent, a cholesterol-lowering drug and Multaq, an anti-arrhythmic drug for atrial fibrillation. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and treatment of venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for patients with osteoarthritis; Stilnox for treatment of insomnia; and Allegra, an anti-histamine for the treatment of seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Receive SAN News and Ratings via Email

Sign-up to receive the latest news and ratings for SAN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange EPA
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
SymbolEPA:SAN
CUSIPN/A
Phone+33-1-53774000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-0.27%
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares1,260,000,000
Market Cap$82,980.00

Sanofi (EPA:SAN) Frequently Asked Questions

What is Sanofi's stock symbol?

Sanofi trades on the EPA under the ticker symbol "SAN."

What price target have analysts set for SAN?

16 Wall Street analysts have issued 1-year price objectives for Sanofi's shares. Their predictions range from €60.00 to €94.00. On average, they expect Sanofi's stock price to reach €77.81 in the next year. This suggests a possible upside of 17.6% from the stock's current price. View Analyst Ratings for Sanofi.

What is the consensus analysts' recommendation for Sanofi?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There are currently 2 sell ratings, 10 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Who are some of Sanofi's key competitors?

Who are Sanofi's key executives?

Sanofi's management team includes the folowing people:
  • Mr. Olivier Brandicourt, CEO & Director (Age 62)
  • Mr. Jérôme Contamine, CFO & Exec. VP (Age 61)
  • Mr. Laurent Gilhodes, Principal Accounting Officer and VP of Corp. Accounting
  • Mr. Bruno Ménard, Chief Information officer
  • Mr. George Grofik, Head of Investor Relations

Has Sanofi been receiving favorable news coverage?

Media coverage about SAN stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sanofi earned a media sentiment score of 0.09 on Accern's scale. They also gave news articles about the company an impact score of 46.00 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

What is Sanofi's stock price today?

One share of SAN stock can currently be purchased for approximately €66.17.

How big of a company is Sanofi?

Sanofi has a market capitalization of $82.98 billion.

How can I contact Sanofi?

Sanofi's mailing address is 54 rue la Boetie, PARIS, 75008, France. The company can be reached via phone at +33-1-53774000.


MarketBeat Community Rating for Sanofi (EPA SAN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  446 (Vote Outperform)
Underperform Votes:  538 (Vote Underperform)
Total Votes:  984
MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe SAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/19/2018 by MarketBeat.com Staff

Featured Article: How Short Selling Works

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.